Table 1.
Biological agents targeting collectins and relevant regulators.
| Biological agent | Type | Effect | Model | Result | Reference |
|---|---|---|---|---|---|
| pdMBL | Plasma-derived protein | Substitutes MBL | Patients | Restores plasma MBL levels, partially restores LP function | (98) |
| rMBL | Recombinant protein | Substitutes MBL | Patients | Restores plasma MBL levels, perfectly restores LP function | (98) |
| 3F8 | Monoclonal antibody | Inhibits MBL | Murine model of STEC-HUS | Attenuates C3d deposition and renal injury | (102) |
| 3F8 | Monoclonal antibody | Inhibits MBL | Murine model of myocardial ischemia/reperfusion | Preserves myocardial injury, reduces infarct size, prevents arterial thrombogenesis | (103) |
| Polyman 9 | Polymannosylated compound | Inhibits MBL | Murine model of controlled cortical impact traumatic brain injury | Improves sensorimotor deficits, promotes neurogenesis and astrogliosis | (104) |
| SFMI-1 | Peptide | Inhibits MASP-1 | In vitro | Prevents C3 and C4 deposition | (106) |
| OMS721 | Monoclonal antibody | Inhibits MASP-2 | Patients with IgA nephropathy, lupus nephritis, membranous nephropathy, or C3 glomerulopathy | In progress | (97) |
| MAP-1 | Endogenous inhibitor | Inhibits MASP-2 | Murine model of myocardial ischemia/reperfusion | Attenuates myocardial injury and thrombogenesis | (104) |
| SFMI-2 | Peptide | Inhibits MASP-2 | In vitro | Prevents C3 and C4 deposition | (106) |
| Pexelizumab | Monoclonal antibody | Inhibits C5 | Patients with ST-segment elevation myocardial infarction | Blunts the elevation in C5a, attenuates the increases of IL-6 | (107) |
| Infliximab | Monoclonal antibody | Inhibits TNF-α | Murine model of intestinal ischemia/reperfusion | Protective effect on damage, decreases serum SP-D levels | (108) |
| Infliximab | Monoclonal antibody | Decreases SP-D | Acute lung injury | Preventive effect on damage, decreases serum SP-D levels | (108) |
LP, lectin pathway; STEC-HUS, Shiga toxin-producing Escherichia coli hemolytic and uremic syndrome.